Company intelligence / Profile preview
NKILT Therapeutics
Houston, Texas, United Statesnkilt.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
NKILT Therapeutics has demonstrated in vitro proof of concept for its CIR-NK cell platform targeting HLA-G, an immune checkpoint broadly expressed in over 50% of human cancers. The company’s lead program is preclinical, with plans to enter clinical trials initially for AML and then expand to solid tumors. Early data show the engineered NK cells can directly kill cancer cells and activate both innate and adaptive immunity by overcoming tumor defense mechanisms.[3][4][5]
- Therapeutic areas
- Oncology
- Modalities
- Allogeneic cell therapyNatural Killer (NK) cell therapyGene-modified immune cells (CIR-NK cells)
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
03
Partnerships
No major pharmaceutical or biotech partnerships publicly disclosed as of May 2025.
Beyond the preview
Go deeper on NKILT Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NKILT Therapeutics.